OssDsign AB (publ)
OSSD.ST
Stockholm Stock Exchange4.09
SEK
+0.02
- -
OssDsign AB (publ)
OSSD.ST
(Stockholm Stock Exchange)
Recent
price
4.09
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- OssDsign AB (publ) (OSSD.ST) designs, manufactures and sells orthobiologics implants and material technology for bone regeneration, primarily focused on its flagship nanosynthetic bone graft OssDsign Catalyst, a putty formulation that engages dual bone formation pathways to promote rapid and reliable bone growth in spinal fusion surgeries and other skeletal defect treatments; the product is cleared for interbody use in any compatible cage based solely on bone graft data, enabling broad on-label applications in orthopedic and spine procedures. Founded in 2011 through a collaboration between Uppsala University and Karolinska University and headquartered at Ulls väg 29C in Uppsala, Sweden, the company listed on Nasdaq First North Growth Market in 2019 and operates globally with key markets in the United States, Germany, Sweden, the United Kingdom, rest of Europe and internationally, generating the majority of revenue from the US. In September 2023, OssDsign announced a strategic shift to become a pure-play orthobiologics company by discontinuing its patient-specific cranial implant business (OssDsign Cranial PSI) by end-2023, allowing full focus on the scalable, high-margin OssDsign Catalyst launched commercially in the US spinal market in late 2021; this refocus supported ongoing clinical initiatives including the multi-center PROPEL spinal fusion registry launched in 2022 and the TOP FUSION study. In June 2025, the company completed a directed share issuance raising approximately SEK 158 million through an accelerated bookbuilding process from existing shareholders and new institutional investors including Adrigo Asset Management and Lancelot Asset Management, coinciding with the launch of its "ScaleToProfit" strategy for 2025-2028 that targets doubling the US sales team by 2026, launching two new products, securing expanded US indications, advancing clinical studies and shifting production toward US-based operations, alongside revised financial goals of over SEK 400 million in sales by 2028 at a 30%+ CAGR and EBIT profitability by late 2025-2028. Previously, OssDsign expanded into orthobiologics via the November 2020 acquisition of Sirakoss Ltd, integrating its nanosynthetic bone graft technology into the portfolio while serving surgeons treating bone defects in competitive landscapes dominated by Stryker, DePuy Synthes and Zimmer Biomet.